|
Parameter
|
Baseline (Mean ± SD, N = 79)
|
Week 2 (Mean ± SD, N = 79)
|
Week 4(Mean ± SD, N = 79)
|
Week 8 (Mean ± SD, N = 79)
|
Week 12 (Mean ± SD. N = 79)
|
|---|
|
Male n (%)
|
70 (89)
|
|
age
|
36.0 ± 11.5
|
|
HLA-B27 (%)
|
98.7
|
|
disease duration (months)
|
7.3 ± 8.0
|
|
NSAIDS (%)
|
82.3
|
|
Psoriasis (%)
|
0
|
|
Rheumatoid Arthritis (%)
|
0
|
|
Inflammatory Bowel Disease
|
0
|
|
BASDAI
|
5.4 ± 1.0
|
3.4 ± 1.5
|
2.2 ± 1.1
|
1.7 ± 1.0
|
1.4 ± 0.8
|
|
BASFI
|
3.2 ± 2.2
|
2.1 ± 1.8
|
1.4 ± 1.5
|
1.1 ± 1.2
|
0.9 ± 1.1
|
|
CRP
|
20.8 ± 32.2
|
3.8 ± 9.9
|
3.7 ± 10.0
|
3.1 ± 4.9
|
3.1 ± 4.2
|
|
ESR
|
28.3 ± 31.1
|
11.4 ± 19.7
|
8.4 ± 13.1
|
6.3 ± 6.8
|
6.5 ± 7.1
|
|
ASDAS
|
3.4 ± 0.8
|
1.8 ± 0.7
|
1.5 ± 0.7
|
1.2 ± 0.6
|
1.1 ± 0.7
|
- SD Standard deviation, BASDAI Bath Ankylosing Spondylitis Di, BASFI Bath Ankylosing Spondylitis Fu, ESR Erythrocyte sedimentation rate, CRP C reactive protein, ASDAS Ankylosing Spondylitis Disease NSADIS Non-steroidal anti-inflammator
